<i>MET</i> Exon 14–altered Lung Cancers and MET Inhibitor Resistance

Abstract

In <i>MET</i> exon 14-altered cancers treated with a MET TKI, a comprehensive analysis of previously unknown and known genomic factors did not identify a genomic mechanism of primary resistance. Instead, MET expression correlated with benefit, suggesting the potential role of interrogating the proteome in addition to the genome in confirmatory prospective trials.